17Q1 Stock Chart & Stats
€2.56
-€0.04(-2.45%)
At close: 4:00 PM EST
€2.56
-€0.04(-2.45%)
Day’s Range― - ―
52-Week Range€1.60 - €3.68
Previous CloseN/A
Volume0.00
Average Volume (3M)111.00
Market Cap
€9.69B
Enterprise Value€39.54K
Total Cash (Recent Filing)€2.45B
Total Debt (Recent Filing)€6.95B
Price to Earnings (P/E)46.4
Beta0.72
Next Earnings
Oct 22, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.96
Shares Outstanding359,977,870
10 Day Avg. Volume1
30 Day Avg. Volume111
Financial Highlights & Ratios
PEG Ratio-2.70
Price to Book (P/B)2.06
Price to Sales (P/S)2.20
P/FCF Ratio56.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.19Price Target Upside63.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)0.14
Revenue Forecast (FY)€2.15B
Bulls Say, Bears Say
Bulls Say
End-to-end CRDMO PlatformPharmaron covers multiple stages of the drug lifecycle, allowing customers to use one provider for connected research, development and manufacturing needs. This broad service model can deepen client relationships, support cross-selling and diversify revenue across project types over the coming quarters.
Solid ProfitabilityThe company remains meaningfully profitable despite slower growth and lower margins than in prior years. Positive earnings provide an operating base for continued investment in laboratories, platforms and capacity, while established margins indicate that the core service model retains economic value.
Acceptable Capital BaseA substantial equity base and moderate TTM leverage provide Pharmaron with a generally workable financial foundation for serving customers and funding operations. Although debt has recently risen, the balance sheet remains acceptable overall and supports resilience relative to a more highly leveraged structure.
Bears Say
Weak Cash ConversionCash generation is materially weaker than reported earnings, limiting the internally funded flexibility available for expansion, debt reduction or shareholder returns. The very low free-cash-flow conversion suggests that reinvestment and working-capital demands may continue to absorb much of the company’s accounting profit.
Meaningful Debt IncreaseThe recent increase in debt raises financial sensitivity even though leverage remains moderate on a TTM basis. Higher obligations can constrain capital allocation and make the business more exposed to refinancing conditions or interest costs, particularly while free cash flow remains thin.
Slower Growth And Margin PressureRevenue is still growing, but the pace has moderated clearly from earlier years and the decline in gross, EBIT and net margins reduces earnings cushion. Sustaining long-term profit growth may therefore require renewed demand, better mix, pricing discipline or improved operating efficiency.
Pharmaron Beijing Co., Ltd. Class H News
17Q1 FAQ
What was Pharmaron Beijing Co., Ltd. Class H’s price range in the past 12 months?
Pharmaron Beijing Co., Ltd. Class H lowest stock price was €1.60 and its highest was €3.68 in the past 12 months.
What is Pharmaron Beijing Co., Ltd. Class H’s market cap?
Pharmaron Beijing Co., Ltd. Class H’s market cap is €9.69B.
When is Pharmaron Beijing Co., Ltd. Class H’s upcoming earnings report date?
Pharmaron Beijing Co., Ltd. Class H’s upcoming earnings report date is Oct 22, 2026 which is in 27 days.
How were Pharmaron Beijing Co., Ltd. Class H’s earnings last quarter?
Pharmaron Beijing Co., Ltd. Class H released its earnings results on Aug 20, 2026. The company reported €0.03 earnings per share for the quarter, missing the consensus estimate of €0.031 by -€0.001.
Is Pharmaron Beijing Co., Ltd. Class H overvalued?
According to Wall Street analysts Pharmaron Beijing Co., Ltd. Class H’s price is currently Undervalued.
Does Pharmaron Beijing Co., Ltd. Class H pay dividends?
Pharmaron Beijing Co., Ltd. Class H does not currently pay dividends.
What is Pharmaron Beijing Co., Ltd. Class H’s EPS estimate?
Pharmaron Beijing Co., Ltd. Class H’s EPS estimate is 0.04.
How many shares outstanding does Pharmaron Beijing Co., Ltd. Class H have?
Pharmaron Beijing Co., Ltd. Class H has 359,977,870 shares outstanding.
What happened to Pharmaron Beijing Co., Ltd. Class H’s price movement after its last earnings report?
Pharmaron Beijing Co., Ltd. Class H reported an EPS of €0.03 in its last earnings report, missing expectations of €0.031. Following the earnings report the stock price went up 6.358%.
Which hedge fund is a major shareholder of Pharmaron Beijing Co., Ltd. Class H?
Currently, no hedge funds are holding shares in DE:17Q1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharmaron Beijing Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.41%
12-Months-Change
Fundamentals
Return on Equity
0.76%
Trailing 12-Months
Asset Growth
24.60%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
17Q1 Stock 12 Month Forecast
Average Price Target
€4.19
▲(63.76% Upside)
Technical Analysis
Genscript Biotech
―
Wuxi Biologics (Cayman)
―
Frontage Holdings Corp.
―
Viva Biotech Holdings
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―